Medexus to Present at the H.C. Wainwright BioConnect 2022 Conference

TORONTO and CHICAGO - Medexus Pharmaceuticals Inc. (the 'Company' or 'Medexus') (TSX: MDP) (OTCQX: MEDXF) announced that Ken d'Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022.

Medexus' presentation will be available on-demand to registered attendees via the conference platform beginning Monday, January 10, 2022 at 7:00 AM Eastern Time.

About Medexus Pharmaceuticals Inc.

Medexus is a leader in innovative rare disease treatment solutions with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company's vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of hematology, auto-immune disease, and allergy. The Company's leading products are: Rasuvo and Metoject, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B - a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall, an innovative prescription allergy medication with a unique mode of action. The Company has also licensed treosulfan, a preparative regimen for allogeneic hematopoietic stem cell transplantation to be used in combination with fludarabine, from medac GmbH for Canada and the United States.

Contact:

Ken d'Entremont

Chief Executive Officer

Medexus Pharmaceuticals Inc.

Tel: [phone]

E-mail: [e-mail]

Marcel Konrad

Chief Financial Officer

Medexus Pharmaceuticals Inc.

Tel: [phone]

E-mail: [e-mail]

Investor

U.S.

Crescendo Communications, LLC

Tel: [phone]

E-mail: [e-mail]

Canada

Victoria Rutherford

Adelaide Capital

Tel: [phone]

E-mail: [e-mail]

(C) 2022 Electronic News Publishing, source ENP Newswire